Innovative Therapies for Children with Cancer (ITCC): Clinical Trial Program

Overall survival from childhood malignancies has dramatically improved, with survival rates now reaching close to 80%. Nevertheless, some types of childhood cancer remain a difficult challenge, and for those who survive the burden of treatment can be considerable. The current paradigm for new cancer therapies is to increase our knowledge of the molecular basis of carcinogenesis, followed by the development of cancer cell-specific therapies. Historically, drug development was focused on adult cancers, and the potential efficacy in childhood malignancies was not considered. The European academic consortium 'Innova…